Healthcare
Live Price
Offline$0.036
-6.33% today
Window Change
-47.20%
Window
Jun 27, 2025 → Feb 12, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 159 bars · Jun 27, 2025 → Feb 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Butterfly Network, Inc. (BFLY-WT) is a Healthcare stock with a market cap of $8.15M. The stock last traded around $0.04 and down 47.2% across the available one-year price window (Jun 27, 2025 → Feb 12, 2026). Baseline metrics include revenue growth of +19.0%, EPS growth of +8.8%, a dividend yield of 0.0%. What stands out right now is revenue +19.0%, EPS +8.8%, free cash flow +63.9% with operating margin -79.1% and ROIC -35.5%. Valuation already assumes a fairly strong business story at price/sales 12.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BFLY-WT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BFLY-WT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BFLY-WT Max Drawdown
-85.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BFLY-WT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$62.6M
-14.7% YoY
FY Net Income
-$32.4M
+80.8% YoY
Free Cash Flow
-$197.1M
-5.1% YoY
Revenue Growth
+19.0%
EPS Growth
+8.8%
Gross Margin
49.2%
Net Margin
-73.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 98M | 82M | 66M | 73M | 63M |
| Gross Profit | 46M | 49M | 17M | 39M | 17M |
| Operating Income | -86M | -74M | -146M | -193M | -193M |
| EBITDA | -67M | -61M | -123M | -163M | -30M |
| Net Income | -77M | -72M | -134M | -169M | -32M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 150M | 89M | 135M | 163M | 423M |
| Total Assets | 297M | 256M | 304M | 418M | 572M |
| Total Liabilities | 101M | 87M | 84M | 92M | 124M |
| Shareholder Equity | 196M | 169M | 220M | 325M | 448M |
| Total Debt | 20M | 23M | 25M | 32M | 29M |
| Net Debt | -130M | -66M | -110M | -131M | -394M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
189M
-11.9% YoY
Capital Expenditures
8M
+57.0% YoY
Free Cash Flow
197M
-5.1% YoY
Key ratios
Gross Margin
49.2%
Operating Margin
-79.1%
Net Margin
-73.6%
ROE
-36.8%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.